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Abstract: Insect pests are responsible for human suffering and financial losses worldwide. New and environmentally safe 
insecticides are urgently needed to cope with these serious problems. Resistance to current insecticides has resulted in a 
resurgence of insect pests, and growing concerns about insecticide toxicity to humans discourage the use of insecticides 
for pest control. The small market for insecticides has hampered insecticide development; however, advances in genomics 
and structural genomics offer new opportunities to develop insecticides that are less dependent on the insecticide market. 
This review summarizes the literature data that support the hypothesis that an insect-specific cysteine residue located at 
the opening of the acetylcholinesterase active site is a promising target site for developing new insecticides with reduced 
off-target  toxicity  and  low  propensity  for  insect  resistance.  These  data  are  used  to  discuss  the  differences  between 
targeting the insect-specific cysteine residue and targeting the ubiquitous catalytic serine residue of acetylcholinesterase 
from the perspective of reducing off-target toxicity and insect resistance. Also discussed is the prospect of developing 
cysteine-targeting anticholinesterases as effective and environmentally safe insecticides for control of disease vectors, 
crop damage, and residential insect pests within the financial confines of the present insecticide market. 
Keywords: Pest control, disease vector control, anti-malaria, crop damage control, irreversible inhibitors, anticholinesterase. 
1. INTRODUCTION 
  New and environmentally safe insecticides are urgently 
needed worldwide to contend with the problems of disease-
carrying,  crop-destroying,  and  residential  insect  pests.  For 
example,  African  malaria  mosquitoes  (Anopheles  gambiae 
sensu stricto) transmit malaria, which sickens approximately 
300  million  and  kills  nearly  1  million  people  every  year. 
Soybean aphids (Aphis glycines) cost U.S. farmers more than 
US$1  billion  in  yield  losses  and  insecticide  purchase  and 
application. Bed bugs, which suck human blood and cause 
acute discomfort, mental stress, and social stigma, are now 
common  in  many  residential  areas.  Insect  resistance  to 
current insecticides and growing concerns about insecticide 
toxicity to humans have contributed to a resurgence of insect 
pests. 
  Currently the cost of developing a traditional insecticide 
is  approximately  US$70  million,  but  the  overall  annual 
public health insecticide market for all diseases and all deve-
loping countries is just US$151 million [1]. This glimpse of 
the  financial  side  of  insecticide  development  and  use 
suggests that a small return on investment is one of the key 
factors  that  hamper  the  development  of  new  insecticides, 
especially  those  for  public  health  purposes.  Nevertheless, 
advancements  in  genomics  and  structural  genomics  offer  
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new opportunities to  identify targets  at  the structural level 
for insecticide development, a spin-off of medical genomics 
research  that  makes  research  and  development  incentives 
less dependent on the insecticide market.  
  In this article, we review literature data pertaining to an 
insect-specific  cysteine  residue  located  at  the  rim  of  the 
acetylcholinesterase (AChE; EC 3.1.1.7) active site and the 
hypothesis  that  this  residue  is  a  novel  target  site  for 
insecticide  development.  With  these  data,  we  discuss  the 
differences  between  targeting  the  insect-specific  cysteine 
residue and targeting the ubiquitous catalytic serine residue 
of AChE from the perspective of reducing off-target toxicity 
and  insect  resistance.  We  also  discuss  the  prospect  of 
developing cysteine-targeting anticholinesterases as effective 
and environmentally safe insecticides for controlling disease 
transmission, crop damage, and residential pests within the 
confines of the current insecticide market.  
2. INSECTS AS DISEASE VECTORS AND CROP AND 
RESIDENTIAL PESTS 
2.1. Disease Vectors 
  Mosquitoes are disease vectors afflicting people in both 
developing and industrialized nations. For example, African 
malaria mosquitoes transmit malaria in sub-Saharan Africa 
[2], northern house mosquitoes (Culex pipiens L.) transmit 
St. Louis encephalitis [3] and West Nile virus [4] in North 
America,  and  yellow  fever  mosquitoes  (Aedes  aegypti  L.) 
transmit dengue, yellow fever, and chikungunya [5] in most 
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tropical and subtropical regions, including the United States. 
Recently, mosquito populations have surged owing both to 
the emergence of insect populations with resistance to cur-
rent  insecticides  and  to  more  and  more  restricted  use  of 
insecticides  in  response  to  concerns  about  environmental 
safety [6]. Novel insecticides are urgently needed to control 
mosquito-borne  diseases,  especially  malaria,  which  contri-
buted to the decline of the  Roman empire and has caused 
grave concern in humans for 500,000 years [7]. According to 
the World Malaria Report 2010 [8], about 765 million of the 
world’s population is at risk of malaria, and an estimated 225 
million cases led to nearly 781,000 deaths in 2009.  
2.2. Crop Pests 
  Aphids are insect pests of grain crops, vegetables, orna-
mental plants,  and fruit trees. For 150 years the greenbug 
(Schizaphis graminum) has been a major pest of small grains 
(e.g.,  sorghum  and  wheat).  Annual  costs  for  greenbug 
control  in  wheat  production  are  approximately  US$100 
million  on  the  Texas  High  Plains  alone  [9].  The  soybean 
aphid (Aphis glycines) costs more than US$1 billion in yield 
losses and insecticide expenditure in the United States [10]. 
During their reproduction season all aphids become female 
to produce progeny through asexual reproduction. This form 
of  reproduction,  which  produces  up  to  18  asexual  gene-
rations per growing season [11],  allows  aphids  to develop 
insecticide resistance rapidly and demonstrates the inherent 
challenge in developing insecticides with low propensity for 
insect resistance. More advanced insecticides are needed to 
address this degree of resistance capability to ensure produc-
tion of food and fiber for an ever-growing world population. 
2.3. Residential Pests 
  Residential  insect  pests  are  of  medical  and  economic 
importance. Wasps deliver painful stings and venom that can 
lead  to  allergenic  responses  and  even  death  from  anaphy-
lactic  shock  [12].  Tribolium  beetles  infest  flour  and  grain 
stores and contaminate food with carcinogenic quinoles [13-
15]. Cockroaches deposit feces that become household aller-
gens  [16].  Regaining  their  formidable  reputation  as  nearly 
ineradicable pests [17, 18], blood-feeding bed bugs (Cimex 
lectularius) can harbor up to 28 human pathogens and cause 
acute  human  discomfort  from  bites  and  feeding,  delayed 
physical reactions to their saliva, allergen production, mental 
stress, and social stigma. Bed bug infestations have become 
increasing common in houses, apartments, hotels, hospitals, 
college  dormitories,  schoolrooms,  and  vehicles  [19-21]. 
Current insecticides for controlling these residential pests are 
either ineffective or unsuitable for use close to food or inside 
dwellings because of the insecticide toxicity to humans or 
other  mammals.  The  latter  underscores  the  importance  of 
reducing  human  and  other  off-target  toxicities  of  new 
insecticides.  
3.  INSECT-SPECIFIC  CYSTEINE  IN  ACETYLCHO-
LINESTERASES 
3.1. Acetylcholinesterase 
  AChE is a serine hydrolase vital for regulating the neuro-
transmitter acetylcholine in mammals, birds, and insects [22-
24]. This enzyme has a deep and narrow active-site gorge 
(Fig. 1), with a catalytic site at the bottom and a peripheral 
site at the entrance [22, 24, 25]. As a serendipitous outcome 
of World War II research on organophosphate nerve agents, 
current anticholinesterase insecticides—such as chlorpyrifos 
and  methamidophos—work  through  phosphorylation  of  a 
serine residue at the AChE catalytic site (Fig. 1), thus dis-
abling  the  catalytic  function  and  causing  incapacitation. 
Because this serine residue is also ubiquitous in AChEs of 
mammals and other species with cholinergic nerves, the use 
of anticholinesterase insecticides to target the serine residue 
causes serious off-target toxicity.  
3.2. Two Insect Acetylcholinesterase Genes 
  Despite reports of resistance-conferring mutations in the 
only AChE gene of the fruit fly (Drosophila melanogaster) 
[26] and biochemical evidence of decreased AChE sensiti-
vity to current insecticides in certain strains of the northern 
house  mosquito  [27,  28],  no  mutations  were  found  in  the 
AChE  gene—which  is  orthologous  to  the  fruit  fly  AChE 
gene—in these anticholinesterase-resistant strains [29]. The 
inability  to  identify  resistance-conferring  mutations  in  the 
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orthologous  gene  eventually  led  to  the  “two-AChE-gene 
hypothesis” that resistance-conferring mutations occur in an 
unidentified gene paralogous to the fruit fly gene [30].  
  This hypothesis was based on the seminal discovery of 
the  paralogous  gene  in  the  greenbug  [31]  and  it  was 
confirmed  subsequently  by  the  paralogous  genes  in  the 
African  malaria  mosquito  [32],  the  cotton  aphid  (Aphis 
gossypii) [33], the northern house mosquito [34], the green 
peach aphid (Myzus persicae) [35], the Japanese encephalitis 
mosquito (Culex  tritaeniorhynchus) [36],  the diamondback 
moth  (Plutella  xylostella)  [37],  the  cotton  bollworm 
(Helicoverpa armigera, AP-AChE: GenBank Accession No. 
AAY59530; AO: [38]), the codling moth (Cydia pomonella) 
[39], the German cockroach (Blattella germanica) [40], the 
human louse (Pediculus humanus) [29], the honeybee (Apis 
mellifera) [41], the oat aphid (Rhopalosiphum padi) [42], the 
English grain aphid (Sitobion avenae) [42], the yellow fever 
mosquito  [43-45],  the  domestic  silkworm  (Bombyx  mori) 
[46], the lesser mealworm (Alphitobius diaperinus) [47], the 
cat  flea  (Ctenocephalides  felis)  [48],  the  wild  silkmoth 
(Bombyx  mandarina)  [49],  the  red  flour  beetle  (Tribolium 
castaneum,  AP-AChE:  GenBank  Accession  No. 
XP_973462;  AO-AChE:  GenBank  Accession  No. 
XP_970774),  the  jewel  wasp  (Nasonia  vitripennis,  AP-
AChE: GenBank Accession No. XP_001600458; AO-AChE: 
GenBank Accession No. XP_001605568), and the sand fly 
(Lutzomyia longipalpis) [50]. Further studies have suggested 
that the paralogous AChE gene is the predominant form of 
AChE,  expressed  in  the  greenbug  [30],  the  diamondback 
moth [37], the human louse [29], and the insecticide-resistant 
Japanese encephalitis mosquito [51].  
  It is now well accepted that, unlike mammals and some 
flies, most disease-transmitting, crop-damaging, and residen-
tial insects have two AChE genes. The flies with one AChE 
gene  include  the  fruit  fly  [52],  the  house  fly  (Musca 
domestica) [53], the horn fly (Haematobia irritans) [54], the 
olive  fly  (Bactrocera  oleae)  [55],  the  oriental  fruit  fly 
(Bactrocera  dorsalis)  [56],  the  Mediterranean  fruit  fly 
(Ceratitis capitata) [57], the stable fly (Stomoxys calcitrans, 
GenBank  Accession  No.  ACT34084),  and  the  Australian 
sheep blowfly (Lucilia cuprina) [58]. The labels ace-1 and 
ace-2  have  been  given  to  the  paralogous  genes  in  the 
literature; to avoid confusion, the insect AChE genes ortho-
logous and paralogous to the AChE gene in the fruit fly are 
termed AO-AChE and AP-AChE, respectively, according to 
the nomenclature given by reference [29]. We use the AO 
and AP nomenclature hereafter. 
3.3. Insect-Specific Cysteine Residue 
  A sequence alignment of nine AChE sequences (humans, 
the  Florida  lancelet  [Branchiostoma  floridae],  the  electric 
ray [Torpedo californica], the African malaria mosquito, the 
northern house mosquito, the greenbug, the cotton aphid, the 
green peach aphid, and the honeybee) identified a cysteine 
residue, Cys289 in the greenbug AP-AChE, that is absent in 
human AChE but conserved in  insect and lancelet  AChEs 
[59]. This alignment [59] along with site-directed mutage-
nesis  work  with  lancelet  AChE  [59]  and  the  previously 
reported sensitivity of aphid AChEs to sulfhydryl inhibitors 
[60, 61] collectively led to discussions on whether Cys289 or 
its  equivalent  in  other  aphid  AP-AChEs  is  located  in  the 
active site [59] and whether it could be used as a target for 
developing selective aphidicides [62].  
  As  apparent  from  the  Protein  Data  Bank  (PDB) 
deposition date of September 10, 2005 for the 3D mosquito 
AChE model (PDB ID: 2AZG) indicating that a large-scale 
sequence analysis and a subsequent 3D model prediction of 
mosquito AP-AChE were performed eight months before the 
online publication of reference [59] in 2006, an independent 
sequence  analysis  of  112  AChE  sequences  in  different 
species identified the same cysteine residue that is absent in 
mammalian,  fish,  and  avian  AChEs  but  conserved  in  AP-
AChEs of 16 insects–most of which are disease vectors as 
well as crop and residential pests (Fig. 2) [63, 64]. The 16 
insects  with  the  conserved  cysteine  residue  included  the 
African malaria mosquito, the northern house mosquito, the 
Japanese encephalitis mosquito, the German cockroach, the 
rice leaf beetle (Oulema oryzae, AP-AChE: GenBank Acces-
sion No. AAN71602), the cotton bollworm, the beet army-
worm (Spodoptera exigua, AP-AChE: GenBank Accession 
No. ABB86963), the codling moth, the diamondback moth, 
the  domestic  silkworm,  the  honeybee,  the  oat  aphid,  the 
greenbug, the cotton aphid, the green peach aphid, and the 
English  grain  aphid.  Recent  sequence  analyses  [48,  65] 
expanded the list to 22 insects with AP-AChEs that have a 
cysteine residue equivalent to Cys289 of the greenbug AP-
AChE by adding the yellow fever mosquito, the cat flea, the 
wild silkmoth, the red flour beetle, the jewel wasp, and the 
sand  fly.  Although  the  AP-AChE  sequences  have  not  yet 
been  reported,  a  recent  biochemical  study  [66]  provides 
direct  evidence  that  yellow  jacket  wasp  (Vespula 
maculifrons), Asian ladybird beetle (Harmonia axyridis), the 
American cockroach (Periplaneta americana), and the bed 
bug (Cimex lectularius) also have AP-AChE equivalent  to 
that in the greenbug.  
  Although  hardly  mentioned  in  the  literature,  a  well-
conserved  cysteine  residue  that  is  37  residues  away  in 
aligned sequence from Cys298 in the greenbug AP-AChE or 
its equivalent in other species is present in all AO-AChEs 
reported  to  date–including  the  AO-AChE  in  the  Colorado 
potato beetle [67]–except for that in the German cockroach. 
According to our sequence  alignment, which is shown for 
the first time in this review (Fig. 2), this residue—Cys290 in 
the fruit fly AO-AChE—is mutated to a non-cysteine residue 
in AChEs of other species. Given the data reported to date, it 
is conceivable that most insect AChEs (AO or AP) have a 
well-conserved  cysteine  residue  that  is  relatively  close  to 
(AO)  or  at  (AP)  the  rim  of  the  active  site  and  that  the 
corresponding residue in non-insect species is mutated to a 
hydrophobic  residue.  Hereafter  we  refer  to  the  cysteine 
residue  in  AO-AChE  or  AP-AChE  as  the  insect-specific 
cysteine residue.  
3.4. Crystal Structures and Computer Models of Insect 
Acetylcholinesterases 
  While  heterologous  expressions  of  African  malaria 
mosquito AP-AChE and some other insect AP-AChEs have 
been reported [48, 49, 68], the only three crystal structures of 
insect AChEs reported to date are the AO-AChE from the 
fruit fly in the free and bound states [69]. Interestingly, all 
three structures resolved at 2.7 Å show that Cys290 in the 
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completely buried by Val311, Thr315, and Gln319 (Fig. 3), 
while  its  neighbor,  Cys292,  forms  a  disulfide  bond  with 
Cys307. In  addition, Cys290 remained the buried conforma- 
tion in all the trajectories saved at 1.0-ps intervals of three 
independent 2-ns-long simulations of the apo fruit fly AO-
AChE crystal structure [Protein Data Bank (PDB) ID: 1QO9 
[69], Yuan-Ping Pang’s unpublished work]. These observa-
tions indicate that the insect-specific cysteine residue in fruit 
fly AO-AChE structures is inaccessible to sulfhydryl agents. 
Considering  Cys289  in  the  greenbug  AP-AChE  or  its 
equivalent in other AP-AChEs as an insecticide target sites 
would be inappropriate without a crystal structure or a credi-
ble  computer  model  of  an  AP-AChE  to  ensure  that  the 
insect-specific cysteine residue is not blocked from conjuga-
 
Fig. (2). Multiple sequence alignment of acetylcholinesterases of insects and other species showing the sequence location of the insect-
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tion  with  sulfhydryl  agents  by  neighboring  residues  or 
bonded to a spatially nearby cysteine. 
 
Fig.  (3).  Close-up  view  of  Cys290,  Cys292,  and  Cys307  in  the 
crystal  structure  of  the  fruit  fly  acetylcholinesterase  (PDB  ID: 
1DX4)  showing  the  physical  blockage  of  Cys290  by  Val311, 
Thr315 and Gln319. 
  Homology  modeling  and  effective  multiple  molecular 
dynamics  simulation  refinement  led  to  a  set  of  computer 
models of AP-AChEs that were made freely available at the 
PDB  and published  together with the large-scale sequence 
analysis described in Section 3.3 [63, 64]. This set includes 
greenbug (PDB ID: 2HCP), English grain aphid (PDB ID: 
2HCQ), and African malaria mosquito (PDB ID: 2AZG) AP-
AChEs.  
  In the models of greenbug and English grain aphid AP-
AChEs,  the  insect-specific  cysteine  residue—Cys289  in 
greenbug AP-AChE—is located at the entrance of the AP-
AChE active site [64]. In the human AChE crystal structure 
[70],  the  residue  spatially  corresponding  to  Cys289  is 
Val294 (Fig. 4). Most importantly, unlike Cys290 in fruit fly 
AO-AChE, Cys289 in these models is not completely buried 
by  neighboring  residues,  and  it  is  spatially  remote  to  any 
cysteine  residues  for  a  disulfide  bond  formation.  In  other 
words,  Cys289  is  accessible  to  sulfhydryl  agents  for 
conjugation.  
 
Fig.  (4).  Overlay  of  the  greenbug  (green)  and  human  (yellow) 
acetylcholinesterases  from  a  perspective  looking  down  onto 
substrate acetylcholine at the catalytic site. 
  Similarly,  the  model  of  African  malaria  mosquito  AP-
AChE  shows  that  its  insect-specific  cysteine  residue  is 
unpaired and accessible to electrophiles binding at the active 
site (Fig. 5) [63]. The spatial equivalent of Cys286 in human 
AChE is Val294 or Phe295 (Fig. 5). These mosquitoes also 
have an arginine residue (Arg339 of malaria mosquito AP-
AChE) at the rim of the AP-AChE active site that appears to 
be  genus  specific  (see  Section  6.3  for  discussion  on  the 
implication of Arg339) [63]. 
 
Fig.  (5).  Overlay  of  the  African  malaria  mosquito  (green)  and 
human  (yellow)  acetylcholinesterases  from  a  perspective  looking 
down onto substrate acetylcholine at the catalytic site. 
  By extrapolating the results above, it is conceivable that 
insect  AP-AChEs  have  a  cysteine  residue  “guard”  at  the 
entrance of the active site, whereas mammalian AChEs have 
a phenylalanine residue as an “usher” for cationic ligands at 
the  entrance  (Fig.  6).  This  structural  difference  between 
mammal  and  insect  species  offers  a  new  opportunity  for 
developing effective and environmentally safe insecticides as 
described below. 
 
Fig.  (6).  Structural  difference  at  the  entrance  of  the  active  site 
between mammalian and insect acetylcholinesterases. 
4.  INSECT-SPECIFIC  CYSTEINE  AS  A  NEW 
TARGET SITE 
  It was known that a native or engineered cysteine residue 
near or at the active site of an enzyme can covalently bond to 
a small molecule that binds, even loosely, at the active site, 
as long as that molecule carries a sulfhydryl moiety [71] or a 
leaving group that is vulnerable to attack by a thiol group 
[72].  Sulfhydryl  reagents  are  also  known  to  form  adducts 
with a cysteine residue at the peripheral site of a mammalian 
AChE engineered with a His287Cys mutation and thereby to 476    Current Drug Targets, 2012, Vol. 13, No. 4  Pang et al. 
interfere  with  substrate  binding  and  consequent  catalytic 
activity [73, 74].  
  In  this  context,  the  hypothesis  that  the  insect-specific 
cysteine  residue  located  at  the  opening  of  the  AP-AChE 
active site would be a promising target site for developing 
new insecticides was reported and discussed [63, 64]. Initial 
support for this hypothesis came from sequence analysis [63, 
64], computer-generated 3D models of AP-AChEs [63, 64], 
and demonstrations of sulfhydryl agents inhibiting enzyme 
catalysis by conjugation with a native or engineered cysteine 
residue at the  active site [71, 72] and of AChE inhibition 
through the blockage of the AChE peripheral site [73, 74].  
  The  advantage  of  this  hypothesis  is  at  least  fourfold. 
First, insecticides that target the insect-specific cysteine resi-
due  should  be  less  toxic  to  mammals  than  current  anti-
cholinesterases  that  target  the  ubiquitous  catalytic  serine 
residue of all AChEs. Second, targeting the cysteine residue 
alleviates  the  resistance  problems  that  have  occurred  with 
current serine-targeting insecticides that have been used for 
decades, because insects have had no opportunity to develop 
resistance  to  cysteine-targeting  insecticides.  Third,  most 
insects appear to have AP-AChE with a free cysteine residue 
at the entrance of the active site; this enables a generic app-
roach to developing cysteine-targeting insecticides. Finally, 
the  hypothesis  offers  a  low-cost  of  development  of  new 
insecticides. Given the small size of the insecticide market, 
this advantage is the most important, as adequate financial 
resources are currently unavailable for the development of 
individualized  approaches  to  a  wide  array  of  problems 
caused by insects.  
5.  INHIBITION  OF  INSECT  ACETYLCHOLINES-
TERASES 
5.1. Irreversible Inhibition of Insect Acetylcholinesterase 
Activity 
  To  test  the  hypothesis  that  the  insect-specific  cysteine 
residue  is  a  viable  target  site,  prototypic  irreversible 
inhibitors (AMTS7–AMTS20; Fig. 7) were reportedly made 
to investigate whether (1) Cys289 in greenbug AP-AChE is 
indeed  accessible  for  conjugation,  (2)  inhibition  of  AP-
AChE can deplete greenbug AChE activity entirely, and (3) 
these  prototypic  cysteine-targeting  inhibitors  can  affect 
human AChE activity [65]. Inspired by the work of reference 
[74], AMTS7–AMTS20 were designed to have a trimethyl-
ammonium group to confer  affinity by the  cation-pi inter-
action with Trp87 at the active site of greenbug AP-AChE 
[22, 24] and a methanethiosulfonate group known to form an 
adduct  preferentially  with  free  cysteine  residues  [75].  A 
crystal structure of AMTS13 in complex with recombinant 
mouse AChE resolved at 2.6 Å [76] suggests that these com-
pounds have the ability to anchor the ammonium group atop 
the indole ring of Trp87 and place the methanethiosulfonate 
group  in  the  vicinity  of  the  free  cysteine  residue  at  the 
peripheral site.  
 
Fig. (7). Chemical structures of AMTS7–AMTS20. 
  These  inhibitors  were  reportedly  tested  for  irreversible 
AChE inhibition by exposure to the total AChE-containing 
homogenate of insect or mammalian samples for a defined 
period  of  time,  after  which  the  unbound  inhibitor  was 
removed  from  AChE  via  extended  dialysis  [65].  A  radio-
metric method devoid of artifacts caused by free thiol groups 
in  samples  or  reagents  was  used  to  determine  total  and 
irreversible AChE inhibition in assays of AChE activity in 
the preparations before and after dialysis, respectively [65].  
  As  shown  in  Fig.  (8A),  the  long-chain  inhibitors 
(AMTS17-AMTS20)  at  6  µM  achieve  nearly  total  and  
 
 
Fig.  (8).  Effects  of  inhibitor  length  and  concentration  on  AChE 
inhibition by AMTSn. A: the length effect on the greenbug and 
human AChE inhibition; B: the length effect on the mosquito and 
human  AChE  inhibition;  C:  the  concentration  effect  on  the 
mosquito and human AChE inhibition. Acetylcholinesterase Target Site  Current Drug Targets, 2012, Vol. 13, No. 4     477 
irreversible inhibition of greenbug AChE but hardly affect 
human  AChE  under  identical  conditions.  These  inhibitors 
also show 95% inhibition of the total AChE activity in the 
African malaria mosquito and >80% inhibition in northern 
house and the yellow fever mosquitoes (Fig. 8B). In addi-
tion,  the  long-chain inhibitors  exhibit selective  irreversible 
inhibition of  total AChE  activity in  soybean  aphids  at the 
same inhibitor concentration [65].  
  Unexpectedly,  the  short-  and  medium-chain  inhibitors 
(AMTS7–AMTS16)  show  slow,  partial,  and  irreversible 
inhibition  of  human  AChE  as  well.  Although  AMTS17–
AMTS20  at  6  µM  showed  no  irreversible  inhibition  of 
human  AChE  [65],  a  full  dose-response  analysis  detected 
irreversible inhibition at inhibitor concentrations of >10 µM 
(Fig.  8C).  The  irreversible  inhibitory  effect  on  the  human 
enzyme by AMTS17–AMTS20 at 100 µM is similar to that 
by AMTS13 at 6 µM [76].  
  Furthermore, AMTS13 reportedly conjugates with gluta-
thione within seconds, although by itself glutathione has no 
detectable  effect  on  AChE  activity  in  extracts  from  mos-
quitoes, human red blood cells, or recombinant human AChE 
[76].  This  observation  led  to  determination  of  the  time 
course  of  irreversible  AChE  inhibition  by  AMTS13.  Of 
mechanistic  importance, 6 µM AMTS13 causes rapid and 
irreversible  inhibition  of  African  malaria  mosquito  AChE, 
reaching  ~50  and  ~100%  irreversible  inhibition  within  10 
and 30 minutes, respectively (Fig. 9A). By contrast, a four-
hour  incubation  was  needed  to  achieve  30%  irreversible 
inhibition  of  recombinant  human  AChE  (Fig.  9B).  Thus, 
irreversible inhibition of mosquito AChE by 6 µM AMTS13 
is fast and nearly complete, whereas that of human AChE is 
slow and partial.  
 
Fig. (9). Time courses of irreversible inhibition for mosquito and 
human AChEs by AMTS13. Extracts of African malaria mosquito 
AChE (AgAChE) and recombinant human AChE (rhAChE) were 
exposed, respectively, to 6 µM AMTS13 at room temperature for 
defined intervals of time terminated by addition of glutathione (to a 
final concentration of 500 µM). Shown is AChE activity in treated 
samples assayed radiometrically. 
  Given  the  complication  of  an  unexpected  irreversible 
inhibition  of  the  human  enzyme,  reactivation  experiments 
were necessarily performed using greenbug AChE samples, 
AMTS13,  and  2-mercaptoethanol  [75],  a  disulfide  bond 
reducing (breaking) agent, to determine whether the obser-
ved  irreversible  AChE  inhibition  was  due  to  the  expected 
conjugation to the insect-specific cysteine residue [65]. The 
reported data shown in Table 1 [65], demonstrate that when 
fresh greenbug and red blood cell extracts were treated for 
two  hours  with  100  mM  2-mercaptoethanol  and  then 
dialyzed, the greenbug AChE pretreated with AMTS13 was 
dramatically reactivated by 2-mercaptoethanol, whereas the 
human AChE activity fell to 21% of the control. The effect 
of 2-mercaptoethanol on the human enzyme is understand-
ably caused by the rupture of the solvent-exposing disulfide 
bond  in  AChE  by  2-mercaptoethanol  that  consequently 
reduces the AChE activity, although 2-mercaptoethanol can 
at the same time cleave the AMTS13 conjugate to reverse 
the inhibition of greenbug AChE by AMTS13 [76]. A simi-
lar result was shown for a mosquito AChE sample [76].  
Table 1.  Reactivation  Studies  of  Greenbug  and  Human 
AChEs  Inhibited  by  AMTS13  Using  2-Mercapto-
ethanol (BME) 
 
Sample  Pretreatment  Treatment  % AChE activity 
Greenbug  None  None  100 
  “  BME 0.5 hr  36 
  “  BME 1 hr  31 
  “  BME 2 hr  21 
  AMTS13  None  1 
  “  BME 0.5 hr  12 
  “  BME 1 hr  17 
  “  BME 2 hr  16 
Human  None  None  100 
  “  BME 0.5 hr  49 
  “  BME 1 hr  44 
  “  BME 2 hr  35 
  AMTS13  None  57 
  “  BME 0.5 hr  28 
  “  BME 1 hr  26 
  “  BME 2 hr  20 
The greenbug and human red blood cell extracts were exposed to AMTS13 (6.0 µM) 
for 1 hr and/or to BME (100.0 mM) for different periods of time. After the exposure(s), 
samples were dialyzed overnight and the AChE activity was measured. Activities are 
mean values of triplicate determinations expressed as percentages of the AChE activity. 
 
  Collectively, the results of the reactivation studies using 
aphid and mosquito samples demonstrate that the inhibition 
of greenbug or mosquito AChEs by AMTS13 resulted from 
conjugation  of  the  [(Me)3N
+(CH2)13S–]  fragment  of 
AMTS13  to  the  insect-specific  cysteine  residue  of  AP-
AChE. The time course and reactivation studies show that 
the slow, partial, and irreversible inhibition of human AChE 
by short- and medium-chain AMTS7–AMTS16 at low con-
centrations  or  by  long-chain  AMTS17–AMTS20  at  high 
concentrations is caused by different inhibition mechanisms.  
5.2. Mechanisms of Irreversible Inhibition 
  Although  the  reported  slow,  partial,  and  irreversible 
inhibition of human AChE by AMTS13 appeared oracular 
and initially led to incorrect speculation about a reaction of 
AMTS13  with  the  catalytic  serine  residue  of  AChE  [65], 
further studies using 2-mercaptoethanol, atomic force micro-
scopy, circular dichroism spectroscopy, X-ray crystallogra-
phy,  time-resolved  fluorescence  spectroscopy,  and  liquid 
chromatography triple quadrupole mass spectrometry repor-
tedly  identified  two  distinct  mechanisms  for  the  observed 
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  The fast, nearly complete, and irreversible inhibition of 
African  malaria  mosquito  AChE  by  6  µM  AMTS13  is 
initiated by a reversible interaction between the ammonium 
group of AMTS13 and Trp84 placing the methanethiosulfo-
nate group at the rim of the active site. This positioning puts 
the  reactive  group  close  to  the  insect-specific  cysteine 
residue  and  facilitates  a  rapid  conjugation  of  the  inhibitor 
with the mosquito AP-AChE. This disulfide bond formation 
mechanism is primarily supported by the reactivation of the 
AMTS13-inhibited insect AChE by 2-mercaptoethanol and 
data from the crystal structure of AMTS13 in complex with 
mouse AChE. 
  The  slow,  partial,  and  irreversible  inhibition  of  human 
AChE by 6 µM AMTS13 is caused by partial denaturation 
of  the  enzyme  induced  by  AMTS13  and/or  micelles  of 
AMTS13.  Evidence  of  this  mechanism  comes  primarily 
from far-UV circular dichroism spectra that show a reduction 
of secondary structures in recombinant mouse AChE treated 
with  AMTS13 for 45 hours as well  as from  atomic force 
microscopy  results  indicating  that  AMTS13  has  a  high 
propensity for micelle formation. This tendency is consistent 
with  the  report  that  alkyltrimethylammonium  halides  with 
12–16  methylenes—in  particular  dodecyl-trimethylammo-
nium halides—are effective surfactants that can denature α-
lactalbumin or β-lactoglobulin [77, 78]. Although methane-
thiosulfonate is slightly hydrophilic, the overall structure of 
AMTS13  is  analogous  to  that  of  dodecyl-trimethyl-
ammonium halides.  
6.  DEVELOPMENT  OF  CYSTEINE-TARGETING 
INSECTICIDES 
6.1. Support for the Cysteine-Targeting Hypothesis 
  Despite  the  complication  of  surfactant-like  inhibitors 
causing  slow,  partial,  and  irreversible  inhibition  of  human 
AChE  and  a  report  that  iodoacetamide-containing  AChE 
inhibitors  do  not  bond  covalently  to  African  malaria 
mosquito AP-AChE [79], the fast, nearly full, and irrever-
sible  inhibition  of  the  insect  AChE  activity  by  AMTSn 
together with the reactivation of AMTSn-inhibited AChEs 
by  2-mercaptoethanol  unequivocally  show  that  the  insect-
specific  cysteine  residue  is,  as  shown  in  independent  3D 
models of the AP-AChEs, indeed accessible for conjugation 
with sulfhydryl agents [65, 76]. In theory cysteine-targeting 
insecticides can be developed to minimize off-target toxicity 
by taking advantage of the species difference in AChEs.  
  At  this  point,  it  is  fair  to  question  whether  selectively 
inhibiting  AP-AChE  but  not  AO-AChE  can  deplete  total 
insect  AChE  activity  and  lead  to  insect  incapacitation. 
Consistent  with  the  reported  preponderance  of  AP-AChE 
over  AO-AChE  [29,  30,  37,  51],  AMTS18  irreversibly 
inactivated >80% of the total AChE activity in greenbug and 
mosquito extracts [65, 76]. This observation could be due to 
either that AO-AChE is poorly extracted and not measured 
in the assay or that AO-AChE is a minor contributor to the 
total acetylcholine-hydrolysis activity in insects. The former 
appears unlikely for several reasons. The extraction condi-
tions  used  extensive  mechanical  homogenization  to  create 
fine  suspensions  from  greenbug  and  mosquito  samples  in 
which all of the AChE should have been accessible to the 
substrate. The assays were performed directly on the suspen-
sions without first removing insoluble  matter using  centri-
fugation  or  filtration.  In  the  reported  preliminary  experi-
ments with the fruit fly—the well-characterized genome of 
which  includes  only  AO-AChE  [52]—the  identical  extrac-
tion protocol rendered abundant fruit fly AChE activity that 
was resistant to AMTS18. It is therefore conceivable from 
the  reported  data  that  inhibition  of  AP-AChE  can  deplete 
total insect AChE activity in greenbug and mosquitoes. This 
means that selectively inhibiting AP-AChE is at least theo-
retically  adequate  to  incapacitate  insects  with  cholinergic 
nerves. 
  To support the cysteine-targeting hypothesis further, it is 
necessary to address the reported reservations about targeting 
the insect-specific cysteine residue [62]. If the understanding 
of reference [62] is correct, the concerns are about (1) the 
poor  reaction  rates  of  two  known  sulfhydryl  agents,  5,5′-
dithiobis(2-nitrobenzoic  acid)  and  N-ethylmaleimide,  for 
conjugation  with  Florida  lancelet  AP-AChE  and  (2)  an 
active-site phenylalanine residue that hampers the reactions 
of these two reagents with the insect-specific cysteine resi-
due.  Neither  5,5′-dithiobis(2-nitrobenzoic  acid)  nor  N-
ethylmaleimide is designed for insect AP-AChEs, and their 
reaction  rates  with  the  lancelet  enzyme  and  the  steric 
hindrance experienced in the lancelet enzyme appear to be 
irrelevant to cysteine-targeting insecticides. What is relevant 
is the reaction rates of sulfhydryl agents tailored for insect 
AP-AChEs. As shown in Fig. (9A), 6 µM AMTS13 causes 
rapid  irreversible  inhibition  of  African  malaria  mosquito 
AChE  achieving  50%  irreversible  inhibition  within  10 
minutes. This fast conjugation with insect enzymes demons-
trated  by  a  primitive  cysteine-targeting  inhibitor  indicates 
that sufficient rates for the reaction of sulfhydryl agents with 
the insect-specific cysteine residue should not be a theore-
tical or practical concern. 
6.2.  Targeting  Cysteine  versus  Serine  Residues  of 
Acetylcholinesterase  
  Mechanistically,  targeting  cysteine  and  serine  residues 
uses the same chemical approach—irreversibly modifying an 
active-site residue leading to physical blockage of the active 
site and subsequent inactivation of the enzyme catalysis. In 
addition, the two approaches share the same enzyme. These 
commonalities  can  lead  to  the  incorrect  perception  that 
targeting  the  cysteine residue of AP-AChE  is  the  same  as 
targeting  the  serine  residue  of  AChE  and  that  cysteine-
targeting  insecticides  are  as  same  as  current  anticholines-
terase  insecticides.  It  is  worthy  of  noting  the  fundamental 
differences between these two approaches, however.  
  First,  cysteine  is  chemically  more  reactive  than  serine. 
This  increased  reactivity  means  that  the  cysteine-targeting 
chemicals can be made less reactive and should, therefore, 
have less off-target toxicity than serine-targeting chemicals 
such as organophosphates or  carbamates.  This disparity  in 
chemical  reactivity  also  means  that  cysteine-targeting 
chemicals are structurally different from those that target the 
serine residue, which magnifies their difference from current 
serine-targeting  insecticides  because  cysteine-targeting 
insecticides will, at least initially, face no insect resistance 
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  Second, the locations of the two residues  in the AChE 
active site are different, meaning that resistance to current 
serine-targeting  insecticides  conferred  by  mutations  in  the 
active site of AChE—for example, the Gly119Ser mutant of 
African  malaria  mosquito  AP-AChE  (GenBank  ID: 
AJ515149  [34])—will  not  affect  cysteine-targeting  inhibi-
tors. According to reported models of insect AP-AChEs [63, 
64], the serine residue is located at the bottom of the active-
site  gorge,  whereas  the  cysteine  residue  is  situated  at  the 
opening of the gorge, and the separation between the alpha 
carbons  of  the  two  residues  ranges  from  15  to  18  Å. 
Structurally,  mutating  the  active-site  residues  to  prevent 
serine-targeting chemicals from  entering the deep gorge  is 
easier than to impeding agents from reaching the peripheral 
cysteine. It is fair to argue that insects could respond to the 
selective pressure of a cysteine-targeting agent by increased 
expression  of  AO-AChE.  This  response  appears  unlikely, 
however, as the northern house mosquito has developed its 
resistance to current insecticides through mutations of AP-
AChE  not  by  elevating  levels  of  AO-AChE  [27-29].  It  is 
therefore conceivable that cysteine-targeting chemicals have 
a lower propensity for insect resistance than serine-targeting 
chemicals. 
  Despite some commonalities with serine-targeting insec-
ticides, cysteine-targeting insecticides have lower off-target 
toxicity and decreased likelihood for insect resistance than 
serine-targeting insecticides owing to their relative chemical 
reactivity  and  the  location  of  the  insect-specific  cysteine 
residue. 
6.3.  The  Prospect  of  Developing  Generic  Cysteine-
Targeting Insecticides 
  Given  the  discovery  process  of  the  insect-specific 
cysteine  residue  and  its  prospects  as  a  new  target  for 
insecticide development, it may be tempting to use genomics 
and structural genomics to discover insecticide targets other 
than AChE. One should not overlook at the current fact that 
limited  financial  resources  are  available  for  insecticide 
development, however. Although new insecticide targets can 
be discovered using genomic and structural genomic studies 
that are now low-cost and “off-the-shelf” commodities, the 
expenses involved in developing a new chemical entity as an 
effective  and  environmentally  safe  insecticide  can  be 
formidably  high  and  potentially  impractical.  Conversely, 
AChE  is  a  well-studied  enzyme  and  abundant  literature 
details the development of effective AChE inhibitors, some 
of  which  are  used  currently  as  insecticides  or  others  as 
clinical drugs for treating Alzheimer’s disease. Developing 
insecticides that target a different residue in AChE should be 
less costly than developing chemicals that target proteins that 
are  not  as  well  studied  as  AChE.  For  the  financial  and 
scientific reasons described in Sections 2–5, we advocate the 
pursuit of generic cysteine-targeting insecticides for effective 
and broad control of disease vectors and crop and residential 
insect pests. 
  Presently no reports on cysteine-targeting chemicals that 
effectively  incapacitate  insects  without  measurable  mam-
malian toxicity have been published, partly because much of 
the current research effort is still directed toward proof of 
concept.  Additionally,  unlike  current  anticholinesterase 
insecticides  that  are  low-hanging  fruits  stemming  from 
World  War  II  research  on  nerve  gas,  cysteine-targeting 
chemicals are high-hanging fruits for the following reasons. 
First, most known alkylating agents or electrophiles cannot 
be used to target the cysteine residue because these agents, 
such as Michael acceptors [80], can cause significant human 
toxicity. Second, it is disadvantageous to establish affinity by 
designing a long-chain molecule such as bis-(7)-tacrine [25] 
that  binds  deep  in  the  active-site  gorge,  because  such 
molecules are associated with a high likelihood that insects 
will  develop  resistance  through  active-site  mutations  of 
AChE, as mentioned above. Third, cysteine-targeting agents 
must  have  the  capability  to  react  quickly  with  cysteine, 
which  opposes  the  low-reactivity  requirement  of  low  off-
target toxicity. A delicate balance exists among these three 
factors  in  designing  cysteine-targeting  insecticides. 
Nevertheless, given recent advancements in structure-based 
molecular  design  such  as  synthesis-based  computer-aided 
molecular design that accounts the feasibility and efficiency 
of  inhibitor  synthesis  in  addition  to  inhibitor  affinity  and 
selectivity [81], we think that cysteine-targeting insecticides 
with in vivo efficacy will be forthcoming.  
  It  has  been  recognized  that  honeybees  and  silkworms 
also  have  AP-AChEs  with  the  insect-specific  cysteine 
residue  [63].  This  fact  raises  a  legitimate  concern  that 
cysteine-targeting insecticides could harm beneficial insects. 
It has been reported that mosquitoes have an arginine residue 
at  the  rim  of  the  AP-AChE  active  site  that  appears  to  be 
genus-specific [63]. It has also been proposed that AP-AChE 
inhibitors  can  be  designed  to  target  two  mosquito-specific 
residues  (e.g.,  Cys286  and  Arg339  in  African  malaria 
mosquito  AP-AChE)  or  target  an  insect-specific  residue 
(Cys289 in greenbug AP-AChE) [76] and an aphid-specific 
conformation  of  an  active-site  residue  in  the  greenbug 
enzyme  [65]  to  reduce  toxicity  to  non-target  insects.  The 
essence of these approaches is the creation of individualized 
insecticides  that  hold  great  promise  for  controlling  insects 
without  off-target  toxicity  and  insect  resistance.  After 
systemic  considerations,  however,  we  think  it  is  currently 
impractical to pursue an individualized insecticide paradigm 
owing to the financial restrictions described in Section 1.  
  Fortunately,  honeybees  and  silkworms  do  not  share 
habitat  with  mosquitoes  or  residential  pests.  A  generic 
cysteine-targeting insecticide has to be developed first, and 
the deployment of this type of insecticide must be carefully 
managed  to  avoid  toxicity  to  honeybees,  silkworms,  and 
other  beneficial  insects.  A  recent  study  shows  that  the 
observed differences in inhibitory potency by the prototypic 
irreversible  inhibitor,  ATMSn,  do  not  exceed  8-fold  [66]. 
This relatively narrow range suggests that the feasibility of 
developing  a  generic  irreversible  inhibitor  that  targets  the 
insect-specific  cysteine  residue  of  AP-AChE  in  various 
insect  pests  is  feasible.  Hopefully,  recognition  of  a  new 
generation  of  insecticides  with  low  off-target  toxicity  and 
low propensity for insect resistance will grow the insecticide 
market  to  the  extent  that  individualized  insecticides  can 
eventually be pursued to reduce toxicity to beneficial insects. 
7. CONCLUSION 
  Unlike  mammals,  most  disease-transmitting,  crop-dam-
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of which has an insect-specific cysteine residue. The cysteine 
of  AP-AChE,  located  at  the  entrance  to  the  active  site,  is 
accessible for rapid conjugation with sulfhydryl agents and 
represents  a new opportunity  to develop  cysteine-targeting 
insecticides. Because cysteine is more reactive than serine—
with  which  current  anticholinesterase  insecticides  are 
designed to react—cysteine-targeting insecticides have lower 
off-target  toxicity and a lower propensity for insect resist-
ance  than  serine-targeting insecticides. Although the deve-
lopment of cysteine-targeting insecticides is not easy and the 
small  insecticide  market  places  financial  constraints  on 
research and development, the abundant literature on AChE 
inhibitor  design  and  the  cost-effectiveness  of  the  develop-
ment  process  make  the  insect-specific  cysteine  residue  a 
viable  target  for  developing  effective  and  environmentally 
safe insecticides to control disease vectors, crop damage, and 
residential insect pests.  
NOTE 
  The  cysteine-containing  AP-AChE  list  now  includes 
those of Asian tiger mosquito (Aedes albopictus, GenBank 
Accession Number [GBAN]: AB218421), bed bug (Cimex 
lectularius, GBAN: AEN69455, JQ349158 [Harlan strain], 
and JQ349159 [Harlan strain]), booklice (Liposcelis bostry-
chophila,  GBAN:  FJ647185;  Liposcelis  decolor,  GBAN: 
FJ647186;  Liposcelis  entomophila,  GBAN:  EU854149), 
human  body louse (Pediculus humanus  corporis, GBAN: 
AB266606), human head louse (Pediculus humanus capitis, 
GBAN:  AB266615),  oriental  tobacco  budworm  (Helico-
verpa  assulta,  GBAN:  DQ001323),  southern  house  mos-
quito  (Culex  quinquefasciatus,  GBAN:  XM_001847396), 
springtail (Orchesella villosa, GBAN: ACL27226), soybean 
aphid (Aphis glycines, GBAN: JQ349160), striped riceborer 
(Chilo  suppressalis,  GBAN:  EF453724),  and  whitefly 
(Bemisia tabaci, GBAN: ABV45413). 
ACKNOWLEDGEMENTS 
  Yuan-Ping  Pang  greatly  appreciates  the  enlightening 
phone  conversation  with  Professor  Sarjeet  Gill  of  the 
University of California Riverside that brought our attention 
to the financial aspect of insecticide development and use. 
We acknowledge the funding from the U.S. Army Medical 
Research  Material  Command  (W81XWH-04-2-0001  and 
W81XWH-08-1-0154  to  YPP)  for  developing  a  generic 
approach  to  irreversible  inhibitors  of  pathogenic  enzymes. 
We are grateful for the financial support from the Minnesota 
Partnership for  Medical Genomics and  Biotechnology (the 
State  of  Minnesota  to  YPP,  SB,  and  DWR)  and  from  the 
U.S. Department of Agriculture (USDA/NIFA 2009-05236 
to  YPP,  SB,  and  DWR)  for  developing  cysteine-targeting 
insecticides to control crop damage. 
REFERENCES 
[1]  Hemingway J, Beaty BJ, Rowland M, Scott TW, Sharp BL. The 
Innovative  Vector  Control  Consortium:  improved  control  of 
mosquito-borne diseases. Trends Parasitol 2006; 22: 308-12. 
[2]  Beier JC. Malaria parasite development in mosquitoes. Annu Rev 
Entomol 1998; 43: 519-43. 
[3]  Monath TP, Tsai TF. St. Louis encephalitis: lessons from the last 
decade. Am J Trop Med Hyg 1987; 37: 40S-59S. 
[4]  Hamer GL, Kitron UD, Goldberg TL, et al. Host selection by Culex 
pipiens mosquitoes and West Nile virus amplification. Am J Trop 
Med Hyg 2009; 80: 268-78. 
[5]  Morrison  AC,  Zielinski-Gutierrez  E,  Scott  TW,  Rosenberg  R. 
Defining challenges and proposing solutions for control of the virus 
vector Aedes aegypti. PLoS Med 2008; 5: e68. 
[6]  Fialka JJ. EPA scientists cite pressure in pesticide study. The Wall 
Street Journal, May 25, 2006. 
[7]  Shah S. The tenacious buzz of malaria. The Wall Street Journal, 
July 10, 2010. 
[8]  World  malaria  report  2010.  Available  at:  http://www.who.int/ 
malaria/world_malaria_report_2010/en/index.html  [accessed 
December 8, 2011]. 
[9]  Lazar  MD,  Michel  GJ,  Weng  Y,  et  al.  In:  Development  of 
greenbug resistance in wheat, 1999 ESA Section Symposium: F3 
Poster  Symposium,  Greenbacks  to  greenbugs:  The  Centennial 
Celebration of the Greenbug's Landing; 1999; pp. 39-45. 
[10]  Ragsdale  DW,  McCornack  BP,  Venette  RC,  et  al.  Economic 
threshold  for  soybean  aphid  (Hemiptera:  Aphididae).  J  Econ 
Entomol 2007; 100: 1258-67. 
[11]  McCornack  BP,  Ragsdale  DW,  Venette  RC.  Demography  of 
soybean aphid (Homoptera: Aphididae) at summer temperatures. J 
Econ Entomol 2004; 97: 854-61. 
[12]  Mosbech  H.  Insect  allergy.  A  comparative  study  including  case 
histories and immunological parameters. Allergy: European Journal 
of Allergy and Clinical Immunology 1984; 39: 543-9. 
[13]  Ladisch RK, Ladisch SK, Howe PM. Quinoid secretions in grain 
and flour beetles. Nature 1967; 215: 939-40. 
[14]  Pappas PW, Wardrop SM. Quantification of benzoquinones in the 
flour  beetles,  tribolium  castaneum  and  tribolium  confusum. 
Preparative Biochemistry and Biotechnology 1996; 26: 53-66. 
[15]  Smith LW, Pratt JJ, Nii I, Umina AP. Baking and taste properties 
of  bread  made  from  hard  wheat  flour  infested  with  species  of 
Tribolium, Tenebrio, Trogoderma and Oryzaeohilus. J Stored Prod 
Res 1973; 6: 307-16. 
[16]  Lehrer  SB,  Horner  WE,  Menon  P,  Stankus  RP.  Comparison  of 
cockroach allergenic activity in whole body and fecal extracts. J 
Allergy Clin Immun 1991; 87: 574-80. 
[17]  Kolb  A,  Needham  GR,  Neyman  KM,  High  WA.  Bedbugs. 
Dermatologic Therapy 2009; 22: 347-52. 
[18]  Throne  JE,  Hallman  GJ,  Johnson  JA,  Follett  PA.  Post-harvest 
entomology  research  in  the  United  States  Department  of 
Agriculture-Agricultural  Research  Service.  Pest  Management 
Science 2003; 59: 619-28. 
[19]  Boase C. Bedbugs - Back from the brink. Pesticide Outlook 2001; 
12: 159-62. 
[20]  Potter MF. A bed bug state of mind. Pest Control Technol 2005; 
33: 82-5. 
[21]  Harlan JH, Faulde MK, Baumann GJ. Bedbugs. In: Bonnefoy X, 
Kampen  H,  Sweeney  K,  editors.  Public  Health  Significance  of 
Urban  Pests.  Copenhagen,  Denmark:  WHO  Regional  Office  for 
Europe; 2008. p. 131-54. 
[22]  Sussman  JL,  Harel  M,  Frolow  F,  et  al.  Atomic  structure  of 
acetylcholinesterase  from  Torpedo  californica:  a  prototypic 
acetylcholine-binding protein. Science 1991; 253: 872-9. 
[23]  Taylor  P,  Radic  Z.  The  cholinesterases:  from  genes  to  proteins. 
Annu Rev Pharmacol Toxicol 1994; 34: 281-320. 
[24]  Raves  ML,  Harel  M,  Pang  Y-P,  Silman  I,  Kozikowski  AP, 
Sussman JL. Structure of acetylcholinesterase complexed with the 
nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997; 4: 57-63. 
[25]  Pang  Y-P,  Quiram  P,  Jelacic  T,  Hong  F,  Brimijoin  S.  Highly 
potent, selective, and low cost bis-tetrahydroaminacrine inhibitors 
of  acetylcholinesterase:  steps  toward  novel  drugs  for  treating 
Alzheimer's disease. J Biol Chem 1996; 271: 23646-9. 
[26]  Mutero  A,  Pralavorio  M,  Bride  JM,  Fournier  D.  Resistance-
associated  point  mutations  in  insecticide-insensitive 
acetylcholinesterase. Proc Natl Acad Sci USA 1994; 91: 5922-6. 
[27]  Malcolm CA, Bourguet D, Ascolillo A, et al. A sex-linked Ace 
gene,  not  linked  to  insensitive  acetylcholinesterase-mediated 
insecticide resistance in Culex pipiens. Insect Mol Biol 1998; 7: 
107-20. 
[28]  Tomita T, Hidoh O, Kono Y. Absence of protein polymorphism 
attributable  to  insecticide-insensitivity  of  acetylcholinesterase  in 
the green rice leafhopper, Nephotettix cincticeps. Insect Biochem 
Mol Biol 2000; 30: 325-33. Acetylcholinesterase Target Site  Current Drug Targets, 2012, Vol. 13, No. 4     481 
[29]  Kono Y, Tomita T. Amino acid substitutions conferring insecticide 
insensitivity  in  Ace-paralogous  acetylcholinesterase.  Pestic 
Biochem Physiol 2006; 85: 123-32. 
[30]  Gao J-R, Zhu KY. Increased expression of an acetylcholinesterase 
gene  may  confer  organophosphate  resistance  in  the  greenbug, 
Schizaphis  graminum  (Homoptera:  Aphididae).  Pestic  Biochem 
Physiol 2002; 73: 164-73. 
[31]  Gao  JR,  Kambhampati  S,  Zhu  KY.  Molecular  cloning  and 
characterization  of  a  greenbug  (Schizaphis  graminum)  cDNA 
encoding  acetylcholinesterase  possibly  evolved  from  a  duplicate 
gene lineage. Insect Biochem Mol Biol 2002; 32: 765-75. 
[32]  Weill M, Fort P, Berthomieu A, Dubois MP, Pasteur N, Raymond 
M. A novel acetylcholinesterase gene in mosquitoes codes for the 
insecticide  target  and  is  non-homologous  to  the  ace  gene  in 
Drosophila. Proc Biol Sci 2002; 269: 2007-16. 
[33]  Li F, Han Z-J. Two different genes encoding acetylcholinesterase 
existing in cotton aphid (Aphis gossypii). Genome 2002; 45: 1134-
41. 
[34]  Weill M, Lutfalla G, Mogensen K, et al. Comparative genomics: 
Insecticide resistance in mosquito vectors. Nature 2003; 423: 136-
7. 
[35]  Nabeshima  T,  Kozaki  T,  Tomita  T,  Kono  Y.  An  amino  acid 
substitution on the second acetylcholinesterase in the pirimicarb-
resistant  strains  of  the  peach  potato  aphid,  Myzus  persicae. 
Biochem Biophys Res Commun 2003; 307: 15-22. 
[36]  Nabeshima T, Mori A, Kozaki T, et al. An amino acid substitution 
attributable to insecticide-insensitivity of acetylcholinesterase in a 
Japanese  encephalitis  vector  mosquito,  Culex  tritaeniorhynchus. 
Biochem Biophys Res Commun 2004; 313: 794-801. 
[37]  Baek  JH,  Kim  JI,  Lee  D-W,  Chung  BK,  Miyata  T,  Lee  SH. 
Identification  and  characterization  of  ace1-type 
acetylcholinesterase  likely  associated  with  organophosphate 
resistance in Plutella xylostella. Pestic Biochem Physiol 2005; 81: 
164-75. 
[38]  Ren X, Han Z, Wang Y. Mechanisms of monocrotophos resistance 
in cotton bollworm, Helicoverpa armigera (Hübner). Archives of 
Insect Biochemistry and Physiology 2002; 51: 103-10. 
[39]  Cassanelli S, Reyes M, Rault M, Carlo Manicardi G, Sauphanor B. 
Acetylcholinesterase mutation in an insecticide-resistant population 
of the codling moth Cydia pomonella (L.). Insect Biochemistry and 
Molecular Biology 2006; 36: 642-53. 
[40]  Kim JI, Jung CS, Koh YH, Lee SH. Molecular, biochemical and 
histochemical characterization of two acetylcholinesterase cDNAs 
from the German cockroach Blattella germanica. Insect Molecular 
Biology 2006; 15: 513-22. 
[41]  Weinstock GM, Robinson GE, Gibbs RA, et al. Insights into social 
insects from the genome of the honeybee Apis mellifera. Nature 
2006; 443: 931-49. 
[42]  Chen  M,  Han  Z.  Cloning  and  sequence  analysis  of  2  different 
acetylcholinesterase  genes  in  Rhopalosiphum  padi  and  Sitobion 
avenae. Genome 2006; 49: 239-43. 
[43]  Anthony N, Rocheleau T, Mocelin G, Lee H-J, Ffrench-Constant 
R.  Clonirig,  sequencing  and  functional  expression  of  an 
acetylcholinesterase  gene  from  the  yellow  fever  mosquito  Aedes 
aegypti. FEBS Lett 1995; 368: 461-5. 
[44]  Mori A, Lobo NF, deBruyn B, Severson DW. Molecular cloning 
and  characterization  of  the  complete  acetylcholinesterase  gene 
(Ace1)  from  the  mosquito  Aedes  aegypti  with  implications  for 
comparative genome analysis. Insect Biochemistry and Molecular 
Biology 2007; 37: 667-74. 
[45]  Nene V, Wortman JR, Lawson D, et al. Genome sequence of Aedes 
aegypti, a major arbovirus vector. Science 2007; 316: 1718-23. 
[46]  Shang J-Y, Shao Y-M, Lang G-J, Gan Y, Tang Z-H, Zhang C-X. 
Expression  of  two  types  of  acetylcholinesterase  gene  from  the 
silkworm, Bombyx mori, in insect cells. Insect Science 2007; 14: 
443-9. 
[47]  Kozaki T, Kimmelblatt BA, Hamm RL, Scott JG. Comparison of 
two  acetylcholinesterase  gene  cDNAs  of  the  lesser  mealworm, 
Alphitobius  diaperinus,  in  insecticide  susceptible  and  resistant 
strains. Arch Insect Biochem Physiol 2008; 67: 130-8. 
[48]  Ilg T, Schmalz S, Werr M, Cramer J. Acetylcholinesterases of the 
cat flea Ctenocephalides felis: identification of two distinct genes 
and  biochemical  characterization  of  recombinant  and  in  vivo 
enzyme activities. Insect Biochem Mol Biol 2010; 40: 153-64. 
[49]  Lang G-J, Zhang X-H, Zhang M-Y,  Zhang C-X. Comparison of 
catalytic  properties  and  inhibition  kinetics  of  two 
acetylcholinesterases from a lepidopteran insect. Pesticide Biochem 
Physiol 2010; 98: 175-82. 
[50]  Coutinho-Abreu  IV,  Balbino  VQ,  Valenzuela  JG,  Sonoda  IV, 
Ramalho-Ortigão  JM.  Structural  characterization  of 
acetylcholinesterase  1  from  the  sand  fly  Lutzomyia  longipalpis 
(Diptera: Psychodidae). J Med Entomol 2007; 44: 639-50. 
[51]  Mamiya  A,  Ishikawa  Y,  Kono  Y.  Acetylcholinesterase  in 
insecticide  resistant  Culex  tritaeniorhynchus:  characteristics 
accompanying insensitivity to inhibitors. Appl Entomol Zool 1997; 
32: 37-44. 
[52]  Adams MD, Celniker SE, Holt RA, et al. The genome sequence of 
Drosophila melanogaster. Science 2000; 287: 2185-95. 
[53]  Walsh  SB,  Dolden  TA,  Moores  GD,  et  al.  IIdentification  and 
characterization  of  mutations  in  housefly  (Musca  domestica) 
acetylcholinesterase involved in insecticide resistance. Biochem J 
2001; 359: 175-81. 
[54]  Temeyer  KB,  Chen  AC.  Identification  and  characterization  of  a 
cDNA  encoding  the  acetylcholinesterase  of  Haematobia  irritans 
(L.) (Diptera: Muscidae). DNA Seq 2007; 18: 85-91. 
[55]  Vontas  JG,  Hejazi  MJ,  Hawkes  NJ,  et  al.  Resistance-associated 
point  mutations  of  organophosphate  insensitive 
acetylcholinesterase, in the olive fruit fly Bactrocera oleae. Insect 
Mol Biol 2002; 11: 329-36. 
[56]  Hsu  J-C,  Haymer  DS,  Wu  W-J,  Feng  H-T.  Mutations  in  the 
acetylcholinesterase  gene  of  Bactrocera  dorsalis  associated  with 
resistance to organophosphorus insecticides. Insect Biochem Mol 
Biol 2006; 36: 396-402. 
[57]  Magaña C, Hernández-Crespo P, Brun-Barale A, et al. Mechanisms 
of resistance to malathion in the medfly Ceratitis capitata. Insect 
Biochem Mol Biol 2008; 38: 756-62. 
[58]  Chen Z, Newcomb R, Forbes E,  McKenzie J, Batterham P. The 
acetylcholinesterase gene and organophosphorus resistance in the 
Australian  sheep  blowfly,  Lucilia  cuprina.  Insect  Biochem  Mol 
Biol 2001; 31: 805-16. 
[59]  Pezzementi L, Rowland M, Wolfe M, Tsigelny I. Inactivation of an 
invertebrate acetylcholinesterase by sulfhydryl reagents: the roles 
of  two  cysteines  in  the  catalytic  gorge  of  the  enzyme.  Invert 
Neurosci 2006; 6: 47-55. 
[60]  Zahavi M, Tahori AS, Klimer F. An acetylcholinesterase sensitive 
to sulfhydryl inhibitors. Biochim Biophys Acta 1972; 276: 577-83. 
[61]  Smissaert  HR.  Reactivity  of  a  critical  sulfhydryl  group  of  the 
acetylcholinesterase from aphids (Myzus persicae). Pest Biochem 
Physiol 1976; 6: 215-22. 
[62]  Rowland M, Tsigelny I, Wolfe M, Pezzementi L. Inactivation of an 
invertebrate  acetylcholinesterase  by  sulfhydryl  reagents:  a 
reconsideration  of  the  implications  for  insecticide  design.  Chem 
Biol Interact 2008; 175: 73-5. 
[63]  Pang  Y-P.  Novel  acetylcholinesterase  target  site  for  malaria 
mosquito control. PLoS ONE 2006; 1: e58. 
[64]  Pang Y-P. Species marker for developing novel and safe pesticides. 
Bioorg Med Chem Lett 2007; 17: 197-9. 
[65]  Pang  Y-P,  Singh  SK,  Gao  Y,  et  al.  Selective  and  irreversible 
inhibitors of aphid acetylcholinesterases: steps toward human-safe 
insecticides. PLoS ONE 2009; 4: e4349. 
[66]  Polsinelli  GA,  Singh  SK,  Mishra  RK,  et  al.  Insect-specific 
irreversible inhibitors of acetylcholinesterase in pests including the 
bed  bug,  the  Eastern  yellowjacket,  German  and  American 
cockroaches,  and  the  confused  flour  beetle.  Chem  Biol  Interact 
2010; 187: 142-7. 
[67]  Zhu KY, Clark JM. Cloning and sequencing of a cDNA encoding 
acetylcholinesterase  in  Colorado  potato  beetle,  Leptinotarsa 
decemlineata (Say). Insect Biochem Mol Biol 1995; 25: 1129-38. 
[68]  Jiang  H,  Liu  S,  Zhao  P,  Pope  C.  Recombinant  expression  and 
biochemical  characterization  of  the  catalytic  domain  of 
acetylcholinesterase-1  from  the  African  malaria  mosquito, 
Anopheles gambiae. Insect Biochem Mol Biol 2009; 39: 646-53. 
[69]  Harel  M,  Kryger  G,  Rosenberry  TL,  et  al.  Three-dimensional 
structures of Drosophila melanogaster acetylcholinesterase and of 
its complexes with two potent inhibitors. Protein Sci 2000; 9: 1063-
72. 
[70]  Kryger G, Harel M, Giles K, et al. Structures of recombinant native 
and E202Q mutant human acetylcholinesterase complexed with the 
snake-venom toxin fasciculin-II. Acta Crystallogr Sect D 2000; 56: 
1385-94. 
[71]  Erlanson DA, Braisted AC, Raphael DR, et al. Site-directed ligand 
discovery. Proc Natl Acad Sci USA 2000; 97: 9367-72. 482    Current Drug Targets, 2012, Vol. 13, No. 4  Pang et al. 
[72]  Pang  Y-P,  Xu  K,  Kollmeyer  TM,  et  al.  Discovery  of  a  new 
inhibitor  lead  of  adenovirus  proteinase:  steps  toward  selective, 
irreversible  inhibitors  of  cysteine  proteinases.  FEBS  Lett  2001; 
502: 93-7. 
[73]  Boyd  AE,  Marnett  AB,  Wong  L,  Taylor  P.  Probing  the  active 
center  gorge  of  acetylcholinesterase  by  fluorophores  linked  to 
substituted cysteines. J Biol Chem 2000; 275: 22401-8. 
[74]  Johnson JL, Cusack B, Hughes TF, et al. Inhibitors tethered near 
the acetylcholinesterase active site serve as molecular rulers of the 
peripheral and acylation sites. J Biol Chem 2003; 278: 38948-55. 
[75]  Smith  DJ,  Kenyon  GL.  Nonessentiality  of  the  active  sulfhydryl 
group of rabbit muscle creatine kinase. J Biol Chem 1974; 249: 
3317-8. 
[76]  Pang  Y-P,  Ekström  F,  Polsinelli  GA,  et  al.  Selective  and 
irreversible  inhibitors  of  mosquito  acetylcholinesterases  for 
controlling malaria and other mosquito-borne diseases. PLoS ONE 
2009; 4: e6851. 
[77]  Viseu  MI,  Melo  EP,  Carvalho  TI,  Correia  RF,  Costa  SMB. 
Unfolding  kinetics  of  β-lactoglobulin  induced  by  surfactant  and 
denaturant:  A  stopped-flow/fluorescence  study.  Biophys  J  2007; 
93: 3601-12. 
[78]  Otzen DE, Sehgal P, Westh P. α-Lactalbumin is unfolded by all 
classes of surfactants but by different mechanisms. J Colloid Interf 
Sci 2009; 329: 273-83. 
[79]  Carlier PR, Anderson TD, Wong DM, et al. Towards a species-
selective  acetylcholinesterase  inhibitor  to  control  the  mosquito 
vector of malaria, Anopheles gambiae. Chem Biol Interact 2008; 
175: 368-75. 
[80]  Chakravarti  SK,  Klopman  G.  A  structural  analysis  of  the 
differential  cytotoxicity  of  chemicals  in  the  NCI-60  cancer  cell 
lines. Bioorg Med Chem 2008; 16: 4052-63. 
[81]  Pang Y-P, Vummenthala A, Mishra RK, et al. Potent new small-
molecule  inhibitor  of  botulinum  neurotoxin  serotype  A 
endopeptidase  developed  by  synthesis-based  computer-aided 
molecular design. PLoS ONE 2009; 4: e7730. 
 
 
Received: August 17, 2010  Revised: December 01, 2011  Accepted: December 09, 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 